Advertisement

Forkhead box M1 transcription factor: a novel target for pulmonary arterial hypertension therapy

  • Li Gu
  • Han-Min LiuEmail author
Review Article

Abstract

Background

Forkhead box M1 (FoxM1), a member of forkhead family, plays a key role in carcinogenesis, progression, invasion, metastasis and drug resistance. Based on the similarities between cancer and pulmonary arterial hypertension, studies on the roles and mechanisms of FoxM1 in pulmonary arterial hypertension have been increasing. This article aims to review recent advances in the mechanisms of signal transduction associated with FoxM1 in pulmonary arterial hypertension.

Data sources

Articles were retrieved from PubMed and MEDLINE published after 1990, including—but not limited to—FoxM1 and pulmonary arterial hypertension.

Results

FoxM1 is overexpressed in pulmonary artery smooth muscle cells in both pulmonary arterial hypertension patients and animal models, and promotes pulmonary artery smooth muscle cell proliferation and inhibits cell apoptosis via regulating cell cycle progression. Multiple signaling molecules and pathways, including hypoxia-inducible factors, transforming growth factor-β/Smad, SET domain-containing 3/vascular endothelial growth factor, survivin, cell cycle regulatory genes and DNA damage response network, are reported to cross talk with FoxM1 in pulmonary arterial hypertension. Proteasome inhibitors are effective in the prevention and treatment of pulmonary arterial hypertension by inhibiting the expression and transcriptional activity of FoxM1.

Conclusions

FoxM1 has a crucial role in the pathogenesis of pulmonary arterial hypertension and may represent a novel therapeutic target. But more details of interaction between FoxM1 and other signaling pathways need to be clarified in the future.

Keywords

Forkhead box M1 Proteasome inhibitor Pulmonary arterial hypertension Signaling pathway 

Notes

Acknowledgements

We thank Prof. Ling Gu for insightful discussions and for the critical reading of this manuscript, and Dr. Xia Guo for language help.

Author contributions

LG contributed to literature review and drafting. HML contributed to concept and design, and critical revision. Both authors approved the final version of the manuscript.

Funding

No external funding was secured for this paper.

Compliance with ethical standards

Ethical approval

Not required.

Conflict of interest

The authors have no conflict of interest.

References

  1. 1.
    Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(Suppl 25):D42–50.CrossRefGoogle Scholar
  2. 2.
    Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119.CrossRefGoogle Scholar
  3. 3.
    Tuder RM, Marecki JC, Richter A, Fijalkowska L, Flores S. Pathology of pulmonary hypertension. Clin Chest Med. 2007;28:23–42, vii.CrossRefGoogle Scholar
  4. 4.
    Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res. 2006;99:675–91.CrossRefGoogle Scholar
  5. 5.
    Lajoie AC, Lauziere G, Lega JC, Lacasse Y, Martin S, Simard S, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016;4:291–305.CrossRefGoogle Scholar
  6. 6.
    Guignabert C, Tu L, Le Hiress M, Ricard N, Sattler C, Seferian A, et al. Pathogenesis of pulmonary arterial hypertension: lessons from cancer. Eur Respir Rev. 2013;22:543–51.CrossRefGoogle Scholar
  7. 7.
    Lam EWF, Brosens JJ, Gomes AR, Koo CY. Forkhead box proteins: tuning forks for transcriptional harmony. Nat Rev Cancer. 2013;13:482–95.CrossRefGoogle Scholar
  8. 8.
    Koo CY, Muir KW, Lam EW. FOXM1: from cancer initiation to progression and treatment. Biochimi Biophys Acta. 2012;1819:28–37.CrossRefGoogle Scholar
  9. 9.
    Li Q, Zhang N, Jia Z, Le X, Dai B, Wei D, et al. Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res. 2009;69:3501–9.CrossRefGoogle Scholar
  10. 10.
    Laoukili J, Stahl M, Medema RH. FoxM1: at the crossroads of ageing and cancer. Biochimi Biophys Acta. 2007;1775:92–102.Google Scholar
  11. 11.
    Kim IM, Ramakrishna S, Gusarova GA, Yoder HM, Costa RH, Kalinichenko VV. The forkhead box m1 transcription factor is essential for embryonic development of pulmonary vasculature. J Biol Chem. 2005;280:22278–86.CrossRefGoogle Scholar
  12. 12.
    Kalin TV, Wang IC, Meliton L, Zhang Y, Wert SE, Ren X, et al. Forkhead Box m1 transcription factor is required for perinatal lung function. Proc Natl Acad Sci USA. 2008;105:19330–5.CrossRefGoogle Scholar
  13. 13.
    Bolte C, Zhang Y, Wang IC, Kalin TV, Molkentin JD, Kalinichenko VV. Expression of FoxM1 transcription factor in cardiomyocytes is required for myocardial development. PLoS ONE. 2011;6:e22217.CrossRefGoogle Scholar
  14. 14.
    Zhu H. Forkhead box transcription factors in embryonic heart development and congenital heart disease. Life Sci. 2016;144:194–201.CrossRefGoogle Scholar
  15. 15.
    Ustiyan V, Wang IC, Ren X, Zhang Y, Snyder J, Xu Y, et al. Forkhead box M1 transcriptional factor is required for smooth muscle cells during embryonic development of blood vessels and esophagus. Dev Biol. 2009;336:266–79.CrossRefGoogle Scholar
  16. 16.
    Zhao YD, Huang X, Yi F, Dai Z, Qian Z, Tiruppathi C, et al. Endothelial FoxM1 mediates bone marrow progenitor cell-induced vascular repair and resolution of inflammation following inflammatory lung injury. Stem Cells. 2014;32:1855–64.CrossRefGoogle Scholar
  17. 17.
    Bolte C, Zhang Y, York A, Kalin TV, Schultz Jel J, Molkentin JD, et al. Postnatal ablation of FoxM1 from cardiomyocytes causes late onset cardiac hypertrophy and fibrosis without exacerbating pressure overload-induced cardiac remodeling. PLoS ONE. 2012;7:e48713.CrossRefGoogle Scholar
  18. 18.
    Zhang S, Teng H, Ding Q, Fan J, Shi W, Zhou Y, et al. FoxM1 involvement in astrocyte proliferation after spinal cord injury in rats. J Mol Neurosci. 2013;51:170–9.CrossRefGoogle Scholar
  19. 19.
    Halasi M, Gartel AL. Targeting FoxM1 in cancer. Biochem Pharmacol. 2013;85:644–52.CrossRefGoogle Scholar
  20. 20.
    Halasi M, Gartel AL. FOX(M1) news–it is cancer. Mol Cancer Ther. 2013;12:245–54.CrossRefGoogle Scholar
  21. 21.
    Myatt SS, Lam EW. Targeting FoxM1. Nat Rev Cancer. 2008;8:242.CrossRefGoogle Scholar
  22. 22.
    Yang H, Wen L, Wen M, Liu T, Zhao L, Wu B, et al. FoxM1 promotes epithelial-mesenchymal transition, invasion, and migration of tongue squamous cell carcinoma cells through a c-Met/AKT-dependent positive feedback loop. Anticancer Drugs. 2018;29:216–26.CrossRefGoogle Scholar
  23. 23.
    Zhang Y, Qiao WB, Shan L. Expression and functional characterization of FoxM1 in non-small cell lung cancer. Onco Targets Ther. 2018;11:3385–93.CrossRefGoogle Scholar
  24. 24.
    Sun Q, Dong M, Chen Y, Zhang J, Qiao J, Guo X. Prognostic significance of FoxM1 expression in non-small cell lung cancer. J Thorac Dis. 2016;8:1269–73.CrossRefGoogle Scholar
  25. 25.
    Chai N, Xie HH, Yin JP, Sa KD, Guo Y, Wang M, et al. FoxM1 promotes proliferation in human hepatocellular carcinoma cells by transcriptional activation of CCNB1. Biochem Biophys Res Commun. 2018;500:924–9.CrossRefGoogle Scholar
  26. 26.
    Lee JJ, Lee HJ, Son BH, Kim SB, Ahn JH, Ahn SD, et al. Expression of FoxM1 and related proteins in breast cancer molecular subtypes. Int J Exp Pathol. 2016;97:170–7.CrossRefGoogle Scholar
  27. 27.
    Kong X, Li L, Li Z, Le X, Huang C, Jia Z, et al. Dysregulated expression of FoxM1 isoforms drives progression of pancreatic cancer. Cancer Res. 2013;73:3987–96.CrossRefGoogle Scholar
  28. 28.
    Briest F, Berg E, Grass I, Freitag H, Kaemmerer D, Lewens F, et al. FoxM1: a novel drug target in gastroEnteropancreatic neuroendocrine tumors. Oncotarget. 2015;6:8185–99.CrossRefGoogle Scholar
  29. 29.
    Wierstra I. FoxM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy. Adv Cancer Res. 2013;119:191–41919.CrossRefGoogle Scholar
  30. 30.
    Bella L, Zona S, de Moraes GN, Lam EW. FoxM1: a key oncofoetal transcription factor in health and disease. Semin Cancer Biol. 2014;29:32–9.CrossRefGoogle Scholar
  31. 31.
    Wang T, Liu Z, Shi F, Wang J. Pin1 modulates chemo-resistance by up-regulating FoxM1 and the involvements of Wnt/β-catenin signaling pathway in cervical cancer. Mol Cellular Biochem. 2016;413:179–87.CrossRefGoogle Scholar
  32. 32.
    Raghavan A, Zhou G, Zhou Q, Ibe JC, Ramchandran R, Yang Q, et al. Hypoxia-induced pulmonary arterial smooth muscle cell proliferation is controlled by forkhead box M1. Am J Respir Cell Mol Biol. 2012;46:431–6.CrossRefGoogle Scholar
  33. 33.
    Dai J, Zhou Q, Tang H, Chen T, Li J, Raychaudhuri P, et al. Smooth muscle cell-specific FoxM1 controls hypoxia-induced pulmonary hypertension. Cell Signal. 2018;51:119–29.CrossRefGoogle Scholar
  34. 34.
    Bourgeois A, Lambert C, Habbout K, Ranchoux B, Paquet-Marceau S, Trinh I, et al. FoxM1 promotes pulmonary artery smooth muscle cell expansion in pulmonary arterial hypertension. J Mol Med (Berl). 2018;96:223–35.CrossRefGoogle Scholar
  35. 35.
    Dai Z, Zhu MM, Peng Y, Jin H, Machireddy N, Qian Z, et al. Endothelial and smooth muscle cell interaction via FoxM1 signaling mediates vascular remodeling and pulmonary hypertension. Am J Respir Crit Care Med. 2018;198:788–802.CrossRefGoogle Scholar
  36. 36.
    Semenza GL. Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiol (Bethesda). 2009;24:97–106.Google Scholar
  37. 37.
    Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006;441:437–43.CrossRefGoogle Scholar
  38. 38.
    Chen T, Zhou Q, Tang H, Bozkanat M, Yuan JX, Raj JU, et al. miR-17/20 controls prolyl hydroxylase 2 (PHD2)/hypoxia-inducible factor 1 (HIF1) to regulate pulmonary artery smooth muscle cell proliferation. J Am Heart Assoc. 2016;5:e004510.Google Scholar
  39. 39.
    Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol. 2011;8:443–55.CrossRefGoogle Scholar
  40. 40.
    Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84:767–801.CrossRefGoogle Scholar
  41. 41.
    Shi Y, Massagué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell. 2003;113:685–700.CrossRefGoogle Scholar
  42. 42.
    Grainger DJ, Metcalfe JC, Grace AA, Mosedale DE. Transforming growth factor-beta dynamically regulates vascular smooth muscle differentiation in vivo. J Cell Sci. 1998;111:2977–88.Google Scholar
  43. 43.
    Bjorkerud S. Effects of transforming growth factor-beta 1 on human arterial smooth muscle cells in vitro. Arterioscler Thromb. 1991;11:892–902.CrossRefGoogle Scholar
  44. 44.
    Upton PD, Morrell NW. The transforming growth factor-bone morphogenetic protein type signalling pathway in pulmonary vascular homeostasis and disease. Exp Physiol. 2013;98:1262–6.CrossRefGoogle Scholar
  45. 45.
    Goumans MJ, Liu Z, ten Dijke P. TGF-beta signaling in vascular biology and dysfunction. Cell Res. 2009;19:116–27.CrossRefGoogle Scholar
  46. 46.
    Chen T, Zhou G, Zhou Q, Tang H, Ibe JC, Cheng H, et al. Loss of MicroRNA-17~92 in smooth muscle cells attenuates experimental pulmonary hypertension via induction of PDZ and LIM domain 5. Am J Respir Crit Care Med. 2015;191:678–92.CrossRefGoogle Scholar
  47. 47.
    Cheng H, Chen T, Tor M, Park D, Zhou Q, Huang JB, et al. A high-throughput screening platform targeting PDLIM5 for pulmonary hypertension. J Biomol Screen. 2016;21:333–41.CrossRefGoogle Scholar
  48. 48.
    Hansmann G, de Jesus Perez VA, Alastalo TP, Alvira CM, Guignabert C, Bekker JM, et al. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest. 2008;118:1846–57.CrossRefGoogle Scholar
  49. 49.
    Soubrier F, Chung WK, Machado R, Grunig E, Aldred M, Geraci M, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(Suppl 25):D13–21.CrossRefGoogle Scholar
  50. 50.
    Levy M, Eyries M, Szezepanski I, Ladouceur M, Nadaud S, Bonnet D, et al. Genetic analyses in a cohort of children with pulmonary hypertension. Eur Respir J. 2016;48:1118–26.CrossRefGoogle Scholar
  51. 51.
    Upton PD, Morrell NW. The transforming growth factor-beta-bone morphogenetic protein type signalling pathway in pulmonary vascular homeostasis and disease. Exp Physiol. 2013;98:1262–6.CrossRefGoogle Scholar
  52. 52.
    Herz HM, Garruss A, Shilatifard A. SET for life: biochemical activities and biological functions of SET domain-containing proteins. Trends Biochem Sci. 2013;38:621–39.CrossRefGoogle Scholar
  53. 53.
    Cohn O, Feldman M, Weil L, Kublanovsky M, Levy D. Chromatin associated SETD3 negatively regulates VEGF expression. Sci Rep. 2016;6:37115.CrossRefGoogle Scholar
  54. 54.
    Jiang X, Li T, Sun J, Liu J, Wu H. SETD3 negatively regulates VEGF expression during hypoxic pulmonary hypertension in rats. Hypertens Res. 2018;41:691–8.CrossRefGoogle Scholar
  55. 55.
    Tuder RM, Chacon M, Alger L, Wang J, Taraseviciene-Stewart L, Kasahara Y, et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol. 2001;195:367–74.CrossRefGoogle Scholar
  56. 56.
    Li F. Survivin study: what is the next wave? J Cell Physiol. 2003;197:8–29.CrossRefGoogle Scholar
  57. 57.
    Cheung CH, Huang CC, Tsai FY, Lee JY, Cheng SM, Chang YC, et al. Survivin-biology and potential as a therapeutic target in oncology. Onco Targets Ther. 2013;6:1453–62.CrossRefGoogle Scholar
  58. 58.
    Blanco I, Ferrer E, Maqueda S, Paul T, Luque N, Tura-Ceide O, et al. Role of survivin in experimental models of pulmonary arterial hypertension. Eur Respir J. 2016;48(Suppl 60):2483.Google Scholar
  59. 59.
    McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest. 2005;115:1479–91.CrossRefGoogle Scholar
  60. 60.
    Wierstra I, Alves J. FoxM1c transactivates the human c-myc promoter directly via the two TATA-boxes P1 and P2. FEBS J. 2006;273:4645–67.CrossRefGoogle Scholar
  61. 61.
    Wierstra I, Alves J. FoxM1c and Sp1 transactivate the P1 and P2 promoters of human c-myc synergistically. Biochem Biophys Res Commun. 2007;352:61–8.CrossRefGoogle Scholar
  62. 62.
    Wang IC, Chen YJ, Hughes D, Petrovic V, Major ML, Park HJ, et al. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol cell biol. 2005;25:10875–94.CrossRefGoogle Scholar
  63. 63.
    Meloche J, Pflieger A, Vaillancourt M, Paulin R, Potus F, Zervopoulos S, et al. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation. 2014;129:786–97.CrossRefGoogle Scholar
  64. 64.
    Zona S, Bella L, Burton MJ, de Moraes GN, Lam EW. FoxM1: an emerging master regulator of DNA damage response and genotoxic agent resistance. Biochim Biophys Acta. 2014;1839:1316–22.CrossRefGoogle Scholar
  65. 65.
    Dupre A, Boyer-Chatenet L, Sattler RM, Modi AP, Lee JH, Nicolette ML, et al. A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol. 2008;4:119–25.CrossRefGoogle Scholar
  66. 66.
    Mizuno S, Bogaard HJ, Kraskauskas D, Alhussaini A, Gomez-Arroyo J, Voelkel NF, et al. p53 Gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice. Am J Physiol Lung Cell Mol Physiol. 2011;300:L753–61.CrossRefGoogle Scholar
  67. 67.
    Hu F, Liu C, Liu H, Xie L, Yu L. Ataxia-telangiectasia mutated (ATM) protein signaling participates in development of pulmonary arterial hypertension in rats. Med Sci Monit. 2017;23:4391–400.CrossRefGoogle Scholar
  68. 68.
    Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res. 2008;14:1649–57.CrossRefGoogle Scholar
  69. 69.
    Bhat UG, Halasi M, Gartel AL. FoxM1 is a general target for proteasome inhibitors. PLoS ONE. 2009;4:e6593.CrossRefGoogle Scholar
  70. 70.
    Bhat UG, Halasi M, Gartel AL. Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells. PLoS ONE. 2009;4:e5592.CrossRefGoogle Scholar
  71. 71.
    Gartel AL. A new target for proteasome inhibitors: FoxM1. Expert Opin Investig Drugs. 2010;19:235–42.CrossRefGoogle Scholar
  72. 72.
    Pandit B, Bhat UG, Gartel AL. Proteasome inhibitory activity of thiazole antibiotics. Cancer Biol Ther. 2011;11:43–7.CrossRefGoogle Scholar

Copyright information

© Children's Hospital, Zhejiang University School of Medicine 2019

Authors and Affiliations

  1. 1.Department of Pediatric Pneumology, West China Second University HospitalSichuan UniversityChengduChina
  2. 2.Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second University HospitalSichuan UniversityChengduChina

Personalised recommendations